Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2017-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reliable and timely detection of acute rejections in renal transplant patients is important to preserve the graft function and to prevent premature graft failure. The current gold standard for the rejection diagnosis is a renal biopsy which is usually performed upon an unexplained decline in the graft function (determined by serum creatinine or clearance). Because of the insensitivity of creatinine determinations and the invasiveness of renal biopsies, non-invasive tests have been suggested to diagnose acute rejection including mass spectrometry (MS) analysis of urine samples.

The ability of MS analysis to detect acute rejection has been demonstrated in small studies on selected patients but evidence is lacking that this test is efficacious in the routine setting of the post-transplant patient care. Based on our previous work that established urine peptide sets for acute rejection by MS, a prospective, multicentre diagnostic phase III study will be executed.

The aim of the study is to prove that this test is as equally effective as the allograft biopsy to detect acute rejection in patients that undergo a biopsy for unexplained renal dysfunction. The perspective of this approach is that the test could be used either in place of the biopsy or as decision guidance whether a biopsy is necessary to confirm the presence of rejection. Another perspective is that the MS test (respectively, a simplified test system derived from this method) could be used in the regular post-transplant surveillance for acute rejection, in place of the relatively insensitive procedure with periodic monitoring of the graft function by creatinine determinations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Acute Rejection in Renal Transplant

NCT00205257

Kidney Transplant

COMPLETED

Urine Testing to Detect Kidney Transplant Rejection

NCT00337220

Kidney Transplantation Kidney Disease Kidney Failure, Chronic

COMPLETED

Urine Biomarker for Kidney Transplant Rejection

NCT05072951

Graft Rejection

NOT_YET_RECRUITING

Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation

NCT00558597

Rejection Lung Transplantation

UNKNOWN

TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation

NCT06801262

Kidney Diseases Kidney Transplant Kidney Disease, End-Stage

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rejection of Renal Transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with a kidney or combined kidney/pancreas transplantation
* Unexplained renal allograft dysfunction within the first year of transplantation
* Renal allograft biopsy, which is clinically indicated to verify or exclude an acute rejection